These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 8826565

  • 21. Isradipine--another calcium-channel blocker for the treatment of hypertension and angina.
    Lopez LM, Santiago TM.
    Ann Pharmacother; 1992 Jun; 26(6):789-99. PubMed ID: 1535246
    [Abstract] [Full Text] [Related]

  • 22. Saga of renin-angiotensin system and calcium channels in hypertensive diabetics: does it have a therapeutic edge?
    Kumar AH, Ramarao P.
    Cardiovasc Drug Rev; 2005 Jun; 23(2):99-114. PubMed ID: 16007228
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of angiotensin II type 1 receptor blocker/calcium channel blocker combination therapy for hypertension: focus on a single-pill fixed-dose combination of valsartan and amlodipine.
    Miura S, Saku K.
    J Int Med Res; 2012 Jun; 40(1):1-9. PubMed ID: 22429340
    [Abstract] [Full Text] [Related]

  • 24. Managing peripheral edema in patients with arterial hypertension.
    Epstein BJ, Roberts ME.
    Am J Ther; 2009 Jun; 16(6):543-53. PubMed ID: 19636244
    [Abstract] [Full Text] [Related]

  • 25. Calcium-channel blocking agents.
    Leonard RG, Talbert RL.
    Clin Pharm; 1982 Jun; 1(1):17-33. PubMed ID: 6764159
    [Abstract] [Full Text] [Related]

  • 26. Calcium-channel blockers for combined systemic hypertension and myocardial ischemia.
    Frishman WH, Charlap S.
    Circulation; 1987 Jun; 75(6 Pt 2):V154-62. PubMed ID: 3552312
    [Abstract] [Full Text] [Related]

  • 27. Use of calcium antagonists in patients with ischemic heart disease and systemic hypertension.
    Frishman WH, Michaelson MD.
    Am J Cardiol; 1997 May 22; 79(10A):33-8; discussion 47-8. PubMed ID: 9186065
    [Abstract] [Full Text] [Related]

  • 28. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.
    Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G.
    Eur Respir J; 1998 Aug 22; 12(2):265-70. PubMed ID: 9727772
    [Abstract] [Full Text] [Related]

  • 29. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul 22; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
    Hilleman DE, Reyes AP, Wurdeman RL, Faulkner M.
    J Hum Hypertens; 2001 Aug 22; 15(8):559-65. PubMed ID: 11494095
    [Abstract] [Full Text] [Related]

  • 31. Risk of Fractures With Concomitant Use of Calcium Channel Blockers and Selective Serotonin Reuptake Inhibitors.
    Desai R, Smith SM, Mohandas R, Brown J, Park H.
    Ann Pharmacother; 2024 Sep 22; 58(9):886-895. PubMed ID: 38078408
    [Abstract] [Full Text] [Related]

  • 32. The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations.
    Jones KE, Hayden SL, Meyer HR, Sandoz JL, Arata WH, Dufrene K, Ballaera C, Lopez Torres Y, Griffin P, Kaye AM, Shekoohi S, Kaye AD.
    Curr Issues Mol Biol; 2024 Jun 22; 46(7):6315-6327. PubMed ID: 39057019
    [Abstract] [Full Text] [Related]

  • 33. Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences.
    Meredith PA, Elliott HL.
    J Hypertens; 2004 Sep 22; 22(9):1641-8. PubMed ID: 15311086
    [Abstract] [Full Text] [Related]

  • 34. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.
    de la Sierra A.
    J Hum Hypertens; 2009 Aug 22; 23(8):503-11. PubMed ID: 19148104
    [Abstract] [Full Text] [Related]

  • 35. Lercanidipine in the treatment of hypertension.
    Beckey C, Lundy A, Lutfi N.
    Ann Pharmacother; 2007 Mar 22; 41(3):465-73. PubMed ID: 17341540
    [Abstract] [Full Text] [Related]

  • 36. Current concepts of pharmacotherapy in hypertension: combination calcium channel blocker therapy in the treatment of hypertension.
    Sica DA.
    J Clin Hypertens (Greenwich); 2001 Mar 22; 3(5):322-7. PubMed ID: 11588412
    [Abstract] [Full Text] [Related]

  • 37. Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics.
    Henneman A, Thornby KA.
    Am J Health Syst Pharm; 2012 Jun 15; 69(12):1038-43. PubMed ID: 22644980
    [Abstract] [Full Text] [Related]

  • 38. [Differential therapy with calcium antagonists].
    Scholze JE.
    Herz; 2003 Dec 15; 28(8):754-63. PubMed ID: 14689111
    [Abstract] [Full Text] [Related]

  • 39. Calcium channel blockers in current medical practice: an update for 1993.
    Luft FC, Haller H.
    Clin Exp Hypertens; 1993 Nov 15; 15(6):1263-76. PubMed ID: 8268889
    [Abstract] [Full Text] [Related]

  • 40. Use of calcium channel blockers in cardiovascular risk reduction: issues in Latin America.
    Alcocer L, Bendersky M, Acosta J, Urina-Triana M.
    Am J Cardiovasc Drugs; 2010 Nov 15; 10(3):143-54. PubMed ID: 20524716
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.